
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera is a promising company with a strong product portfolio, highlighted by the success of its MRD test, Signatera, in predicting survival and potential for expansion. Its strong financial performance and expected revenue growth, along with upcoming catalysts, make it an attractive investment opportunity. However, Natera will need to navigate competition and maintain investor interest in order to continue its success.
Bears say
Natera is a company with a promising portfolio of advanced personalized diagnostic offerings in the areas of oncology, organ health, and women's health. However, its overreliance on Signatera, and the potential for penetration of MRD testing to stall, make it a risky investment. Additionally, the company's inconsistent track record of catalyst realization and the potential for ASP expansion to stall could hinder future growth, and its current valuation is already at a premium to its peers.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares